Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication
- 1 July 2000
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 14 (11) , 1481-1488
- https://doi.org/10.1097/00002030-200007280-00003
Abstract
To model the dynamics of HIV-1 rebound in patients receiving suboptimal therapy after suppression of plasma viremia to < 200 copies/ml by triple combination therapy. Mathematical modeling of data from 23 patients switched to indinavir maintenance therapy after viral replication was suppressed with a combination of indinavir, zidovudine and lamivudine. Modeling of HIV-1 rebound among 24 patients on zidovudine/lamivudine maintenance was also performed for comparison. Evaluation of slopes of rebound and of their heterogeneity; calculation of the basic reproductive number (R o, the number of newly infected cells arising from each productively infected cell); regression analyses for predictors of the slope of rebound. Rebound of plasma HIV RNA followed a sigmoid curve with an initial exponential phase. There was significant heterogeneity in the slopes of rebound for individual patients (P < 0.001). In the indinavir maintenance rebounds, the average initial slope was estimated to be 0.587/day (doubling time 1.2 days). The slopes of rebound in patients on zidovudine/lamivudine maintenance tended to be less steep on average (P = 0.025). Among patients taking indinavir maintenance, the average R o for the initial rebound of viremia was 4.3; in multivariate regressions, the slope of rebound was steeper during early rebound and in patients with higher viral load at the start of triple therapy or a higher CD4 cell count when indinavir monotherapy was initiated. The slope was less steep in patients with a greater increase in the number of CD4 cells during triple therapy. The rates of viral load increase among patients with viral rebound while receiving less than triple therapy are similar to those reported in patients interrupting therapy. Variability among patients may depend on viral fitness, target cell availability and extent of immune reconstitution.Keywords
This publication has 23 references indexed in Scilit:
- Drug Susceptibility in HIV Infection After Viral Rebound in Patients Receiving Indinavir-Containing RegimensJAMA, 2000
- HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppressionProceedings of the National Academy of Sciences, 1999
- Mechanistic Studies Examining the Efficiency and Fidelity of DNA Synthesis by the 3TC-Resistant Mutant (184V) of HIV-1 Reverse TranscriptaseBiochemistry, 1999
- Rate of HIV-1 RNA rebound upon stopping antiretroviral therapyAIDS, 1999
- HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatmentAIDS, 1999
- Maintenance Antiretroviral Therapies in HIV-Infected Subjects with Undetectable Plasma HIV RNA after Triple-Drug TherapyNew England Journal of Medicine, 1998
- Antiretroviral Drug Resistance Testing in Adults With HIV InfectionJAMA, 1998
- Mathematical Analysis of Antiretroviral Therapy Aimed at HIV-1 Eradication or Maintenance of Low Viral LoadsJournal of Theoretical Biology, 1998
- Quantitative Image Analysis of HIV-1 Infection in Lymphoid TissueScience, 1996
- HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation TimeScience, 1996